| acute coronary syndrome | versus clopidogrel No demonstrated result for efficacy prasugrel inferior to clopidogrel in terms of all bleeding (major and minor) in TRITON-TIMI 38, 2007 prasugrel inferior to clopidogrel in terms of Major bleeds in TRITON-TIMI 38, 2007 prasugrel inferior to clopidogrel in terms of fatal bleeding in TRITON-TIMI 38, 2007 | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| JUMBO-TIMI 26, 2005 | prasugrel vs clopidogrel | | | cardiovascular death, MI, stroke 0.78 [0.47; 1.31] All cause death ∞ [NaN; ∞] Non–CABG-related TIMI major bleeding 0.59 [0.10; 3.49] Major or minor TIMI bleeding 1.43 [0.40; 5.09] | | TRILOGY ACS (overall population), 2012 | prasugrel vs clopidogrel | | | all cause death 0.94 [0.82; 1.08] all bleeding (major and minor) 1.26 [0.94; 1.69] Major bleeds 1.21 [0.83; 1.77] Vasc deaths 0.93 [0.80; 1.08] fatala and non fatal stroke 0.90 [0.64; 1.26] fatal and non fatal MI 0.96 [0.84; 1.10] fatal bleeding 0.78 [0.29; 2.09] death, MI, stroke 0.96 [0.87; 1.06] | | TRITON-TIMI 38, 2007 | prasugrel vs clopidogrel | Vasc events 0.82 [0.74; 0.91] revascularization 0.67 [0.55; 0.82] Non-fatal MI 0.76 [0.68; 0.86] | all bleeding (major and minor) 1.31 [1.11; 1.55] Major bleeds 1.31 [1.03; 1.68] fatal bleeding 4.19 [1.58; 11.10] | all cause death 0.95 [0.78; 1.16] Vasc deaths 0.88 [0.70; 1.11] Non-fatal stroke 1.01 [0.71; 1.45] |
| Trial | Treatments | Patients | Method |
|---|
| JUMBO-TIMI 26, 2005 | Prasugrel 3 doses (n=650) vs. clopidogrel 300mg loading dose
followed by 75 mg daily) (n=254) | patients undergoing elective or urgent percutaneous coronary intervention | double blind Parallel groups Sample size: 650/254 Primary endpoint: non–CABG-related bleeding FU duration: 30 days phase 2 | | TRILOGY ACS (overall population), 2012 | prasugrel 10 mg daily (n=4663) vs. clopidogrel 75 mg daily (n=4663) | patients with acute coronary syndromes selected for a final treatment
strategy of medical management without revascularization
within 10 days after the index event | double-blind Parallel groups Sample size: 4663/4663 Primary endpoint: cardiovascular events FU duration: 17 months (median) | | TRITON-TIMI 38, 2007 | prasugrel 60-mg loading dose
and 10-mg daily maintenance dose, for 6 to 15 months (n=6813) vs. clopidogrel (a 300-mg loading dose and a
75-mg daily maintenance dose) for 6 to 15 months (n=6795) | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled
percutaneous coronary intervention | double blind Parallel groups Sample size: 6813/6795 Primary endpoint: cardiovascular death, nonfatal MI, or nonfatal FU duration: |
|
| percutaneous coronary intervention | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| TRITOM TIMI 38 (PCI subgroup), 2009 | prasugrel vs clopidogrel | | | |
| Trial | Treatments | Patients | Method |
|---|
| TRITOM TIMI 38 (PCI subgroup), 2009 | prasugrel (60 mg loading, 10 mg maintenance) (n=1769) vs. clopidogrel (300 mg loading, 75 mg maintenance) (n=1765) | subgroup of patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction | Sample size: 1769/1765 Primary endpoint: FU duration: |
|
| percutaneous coronary intervention | versus clopidogrel No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| JUMBO-TIMI 26, 2005 | prasugrel vs clopidogrel | | | cardiovascular death, MI, stroke 0.78 [0.47; 1.31] All cause death ∞ [NaN; ∞] Non–CABG-related TIMI major bleeding 0.59 [0.10; 3.49] Major or minor TIMI bleeding 1.43 [0.40; 5.09] |
| Trial | Treatments | Patients | Method |
|---|
| JUMBO-TIMI 26, 2005 | Prasugrel 3 doses (n=650) vs. clopidogrel 300mg loading dose
followed by 75 mg daily) (n=254) | patients undergoing elective or urgent percutaneous coronary intervention | double blind Parallel groups Sample size: 650/254 Primary endpoint: non–CABG-related bleeding FU duration: 30 days phase 2 |
|
